Elite Pharmaceuticals Inc (ELTP)

[Couch]

Value is definitely beginning to return to this stock now that Nasrat Hakim ~~~ The Closer has become the CEO.

Absolutely ~~ Elite will be PRing their 3rd Patent related to their ART later this month 21-28....Feb Elite will PR their highest quarterly revenue in the history of the company......and let me see what else.....Oh yeah!

Elite has met the goal of starting the bio study for ELI-201 in December. A pivotal bioequivalence study for a second abuse deterrent product is scheduled to begin dosing in January 2014, and the pivotal bioequivalence study for ELI-201 is scheduled to begin dosing in March 2014. The bioequivalence studies for these opioid abuse deterrent products are being conducted under the direction of Camargo Pharmaceutical Services.

“The start of the ELI-201 pilot study marks a major milestone for the development of products utilizing our proprietary abuse deterrent technology,” said Nasrat Hakim, Elite’s President and CEO. “I am extremely pleased with the progress Elite has made with the development of this technology. We have set several initiatives in motion and all of our research and development projects are on or ahead of schedule. We appreciate the guidance and expertise that has been provided by Camargo and look forward to this next phase for the Company.”